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ABSTRACT 
PURPOSE: We report cardiac events in the Persephone trial which compares six to 
twelve months adjuvant trastuzumab in women with confirmed HER2 positive, early 
stage breast cancer. 
 
PATIENTS AND METHODS: Clinical cardiac events were defined as any of the 
following, symptoms and/or signs of congestive heart failure (CHF) and new or altered 
CHF medication.  In addition left ventricular ejection fraction (LVEF) was measured at 
baseline and then 3-monthly for 12 months. 
 
RESULTS: 2500 patients, aged 22-82, were included; 1251 randomised to 12-months 
and 1249 to 6-months trastuzumab. 93% (2335/2500) received anthracyclines, 49% 
of these (1136/2335) with taxanes. Cardiotoxicity delayed treatment in 6% of 12-month 
and 4% of 6-month patients (p=0.01), and stopped treatment early in 8% (96/1214) of 
12-month and 4% (45/1216) of 6-month patients (p<0.0001). Between 7 and 12 
months, more 12-month than 6-month patients had LVEFs<50% (8% vs 5%; p=0.004). 
LVEFs showed quadratic change over time and 6-month patients had a more rapid 
recovery (p=0.02). In a landmark analysis twice as many 12-month patients, free of 
cardiac events at 6 months, had cardiac problems in months 7 to 12 (6% [66/1046] vs 
3% [29/1035] of 6-month patients (p=0.0002)). Lower baseline LVEF predicted more 
cardiac dysfunction in both arms (reference >65%: 55-<65% OR 1.61 [95%CI 1.26-
2.04]; <55% OR 5.22 [3.42-7.95]) as did increasing age (reference <50: 50-59 OR 
1.58 [1.17-2.12], 60-69 OR 1.91 [1.42-2.57]) 70+ OR 2.72 [1.82-4.08]). Two factors 
were associated with higher risk of cardiac events for 12-month compared with 6-
month patients: >3 cycles of anthracycline (OR 1.43 [1.06-1.92] and 1.12 [0.81-1.55] 
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respectively); and prior cardiac medication (OR 5.88 [2.55-13.54] and 12.47 [5.14-
30.25]).  
 
CONCLUSION: We demonstrate significantly fewer cardiac events from 6 months 
adjuvant trastuzumab compared with 12 months. This cardiac signal adds importance 
to the question of the optimum duration of adjuvant trastuzumab treatment. If 6 months 
is proven to have non-inferior outcomes to 12 months treatment, these data would 
support 6 months as the standard of care. 
  
Page 5 of 32 
 
 
INTRODUCTION 
Trastuzumab has transformed the treatment of HER2 positive breast cancer both in 
the adjuvant and the metastatic settings. The results of the US and international 
adjuvant trastuzumab trials published in 2005-7 (Piccart-Gebhart et al, 2005; Romond 
et al, 2005; Hortobagyi, 2005; Slamon et al, 2011), resulted in a paradigm shift in 
treatment and established 12 months of adjuvant trastuzumab as the standard of care. 
Previously HER2 positive breast cancer was associated with poor outcomes. The 
METABRIC genomic analysis of nearly 2000 breast cancer patients, serves as a 
reminder of the poor prognosis particularly for high risk ER negative HER2 positive 
patients prior to the introduction of adjuvant trastuzumab (Curtis et al, 2012; Dawson 
et al, 2013). The HERA trial has reported long term follow-up results (Goldhirsch A et 
al, 2013) which have demonstrated a robust improvement in disease-free and overall 
survival with 12 months of adjuvant trastuzumab but no incremental clinical benefit 
from extending adjuvant treatment to 24 months.  
 
Cardiac dysfunction with reduced left ventricular ejection fraction has been recognized 
as a side effect of trastuzumab therapy since the early days of its use (Seidman et al, 
2002)8 and has since been reported in all adjuvant trials (Tan-Chiu et al, 2005; Suter 
et al, 2007; Procter et al, 2010; de Azambuja et al, 2014; Perez et al, 2008; Russell et 
al, 2010). The pathophysiology of the observed cardiac toxicity is not completely 
understood. HER2 receptors are present on cardiac myocytes, and without normal 
HER2 function, there may be accumulation of reactive oxygen species resulting in 
dysfunction (Zeglinski et al, 2011). Trastuzumab may also impair mitochondrial 
function through intracellular downstream events resulting in ATP depletion and 
therefore contractile dysfunction (Force, Krause, van Etten, 2007). Sequential cardiac 
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stresses from anthracycline administration preceding trastuzumab treatment are also 
likely to significantly contribute to cardiac problems (Ewer et al, 1999; Ewer et al, 
2005). The PHARE trial, which has also looked at reducing trastuzumab duration to 6 
months compared with the standard of 12 months (Pivot et al, 2013), demonstrated a 
reduction in cardiac dysfunction to 4% in the 6 month arm (Pivot et al, 2015). The 
cardiac data from the PHARE (Pivot et al, 2015), HERA (Tan-Chiu et al, 2005; Suter 
et al, 2007; Procter et al, 2010; de Azambuja et al, 2014) trials and the US studies 
(Perez et al, 2008; Russell et al, 2010) show a clear relationship between the duration 
of trastuzumab exposure and incidence of cardiac dysfunction. Notwithstanding this 
important finding, there are increasing numbers of patients on trastuzumab for long 
periods of time in the metastatic setting, and in these patients there seems little 
objective data to indicate a cumulative dose form of toxicity as seen with 
anthracyclines (Mantarro et al, 2016; Jensen, 2006). 
 
There would be clear advantages in reducing the risk of cardiac dysfunction, if the 
duration of adjuvant trastuzumab could be shortened to 6 months or less without 
sacrificing clinical efficacy. From 2007 to the end of July 2015, the Persephone trial 
randomized HER2 positive patients to either 6 or 12 months trastuzumab (Earl et al, 
2014). We present here the cardiology sub-study with the pre-specified secondary 
endpoint of cardiac function in the first 2500 patient cohort. The Persephone trial was 
designed to ‘map onto standard practice’ in the UK and therefore our results will be 
applicable to ‘real world patients’. 
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PATIENTS AND METHODS 
Study design 
The Persephone trial is a UK phase III randomized non-inferiority trial comparing 6 
months of trastuzumab to the standard 12 month duration in women with histologically 
confirmed HER2 positive early invasive breast cancer receiving a standard 
chemotherapy regimen in the adjuvant or neo-adjuvant setting. These patients had 
stage I-IIIa disease. This trial was approved by Multi-Research Ethics Committee 
(07/MRE08/35), is conducted in accordance with the declaration of Helsinki and 
supported by the NCRN (No 4078). 
  
The primary endpoint is disease-free survival (DFS), with cardiac function a secondary 
endpoint. The Data and Safety Monitoring Committee reviewed full cardiac data on 
the first 2500 patients and advised both a reduction in frequency of LVEF 
measurements from 3-monthly to the new UK standard practice (minimum 4-monthly) 
(Jones et al, 2009) as well as the publication of the sub-study cardiac event data ahead 
of the primary endpoint of the trial. 
 
These 2500 patients were randomized to receive trastuzumab intravenously (IV) for 
either 12 months (18 cycles) or 6 months (9 cycles) using a schedule of one loading 
dose of 8mg per kilogram of body weight (/kg) IV followed by 3-weekly maintenance 
doses of 6mg/kg IV. Trastuzumab administration could be concurrently with taxane 
(but not anthracyclines) or sequentially. 
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Participants 
Inclusion criteria were: histological diagnosis of invasive breast cancer; no evidence 
of metastatic disease; known hormone receptor status; overexpression of HER2 
receptor; bilateral breast cancers provided one of the tumours overexpresses HER2 
receptor; clear indication for neo-adjuvant or adjuvant chemotherapy based on clinical 
and histopathological features; patient fit to receive neo-adjuvant or adjuvant 
chemotherapy and trastuzumab in the opinion of the responsible physician; no 
previous diagnosis of malignancy unless (i) managed by surgical treatment only and 
disease-free for 10 years or (ii) previous basal cell carcinoma, cervical carcinoma in 
situ or ductal carcinoma in situ of the breast; non-pregnant and non-lactating, with no 
intention of pregnancy during chemotherapy, and agrees to adopt adequate 
contraceptive measures if pre-menopausal and sexually active; no concomitant 
medical or psychiatric problems that might prevent completion of treatment or follow-
up; patients 18 years or older; and written informed consent for the study given at any 
time before the 10th cycle of trastuzumab. Exclusion criteria were: significant 
concomitant cardiac disease or other co-morbidity which in the opinion of the 
responsible physician added to the risks associated with trastuzumab or cytotoxic 
chemotherapy; inability to comply with protocol requirements; and patients having 
already received more than 9 cycles of trastuzumab prior to randomisation. 
In particular participants should have no significant cardiac disease or co-morbidity 
that added to the cardiac risks associated with trastuzumab and chemotherapy, in the 
opinion of the principal investigator (PI). However, Persephone was a trial designed to 
'map onto standard practice' and therefore did not exclude any patients who, in the 
opinion of the PIs at recruiting sites, would otherwise be considered fit enough to 
receive chemotherapy and the standard of 12 months adjuvant trastuzumab.  
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Randomisation and masking 
The trial was open label and we randomly assigned patients (1:1) to 12-months or 6-
months trastuzumab using a central computerized minimization procedure. 
Stratification by minimization was done by ER status, chemotherapy type, 
chemotherapy timing and trastuzumab timing according to the protocol. 
Randomization was at any point prior to cycle 10 of trastuzumab. 
 
Cardiac endpoints 
‘Clinical cardiac dysfunction’ was defined as any or all of the following: symptoms or 
signs of CHF or new / altered cardiac medication prescribed during the 12 months 
after starting trastuzumab. Patients on trastuzumab were reviewed by the study team 
on site every 3 weeks, and every 3 months ‘clinical cardiac dysfunction’ was reported 
on the case record forms, to the trials office. Patients were questioned about 
symptoms of CHF and if these were present, examined by a physician for signs of 
CHF. Other cardiac events included cardiac death, defined as death with at least one 
cause recorded relating to a cardiac issue. ‘Low LVEF’ was a cardiac endpoint, and 
was defined as left ventricular ejection fraction (LVEF) measurement < 50% at any 
point, or a report recording systolic function below normal but without LVEF values. 
LVEF was recorded at the start of trastuzumab (baseline) and at 3-monthly intervals 
for 12 months in both randomized arms and regardless of the timing of randomization 
with respect to start of trastuzumab. Echocardiography (ECHO) or multi-gated 
acquisition cardiac scanning (MUGA) were undertaken, preferably using the same 
method throughout for each individual. Although we recognize that these two methods 
may produce results differing in some aspects, ECHO and MUGA were treated 
equivalently in the data analysis. Cardiac monitoring did not routinely continue after 
12 months, although some later LVEF measurements were available. 
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Treatment modifications 
Patients developing clinical cardiac dysfunction underwent full cardiac assessment. If 
LVEF fell below 50%, the protocol advised ‘holding’ trastuzumab and repeating LVEF 
at 6 week intervals until LVEF returned to ≥ 50%. Only two delays for a maximum of 3 
months on account of cardiac toxicity were allowed before trastuzumab was 
discontinued permanently. In the case of New York Heart Association (NYHA) class 
III/IV heart failure symptoms (breathlessness at rest or on minimal exertion) 
trastuzumab was permanently discontinued even after resolution of symptoms or 
normalization of LVEF with treatment (Nomenclature and Criteria for Diagnosis of 
Diseases of the Heart and Great Vessels pp. 253–256, 1994; Raphael et al, 2007). 
 
Statistical analysis 
Randomized treatment arms and assessment periods were compared by the number 
of patients reporting treatment modification or cardiac endpoints and course delivered 
dose intensity (CDDI) (Earl et al, 2008) of trastuzumab using chi-squared tests with 
continuity corrections. Patients’ baseline LVEF and the relative changes at 6 and 12 
months were assessed using Wilcoxon signed rank tests and Wilcoxon rank sum test. 
 
Random effects modelling was applied to patients’ LVEF over time, and results 
presented graphically as the mean patient values over time for each treatment arm as 
predicted by the model. Further random effects modelling investigated the influence 
of chemotherapy type, trastuzumab timing and number of anthracycline cycles. The 
influence of predictive factors for development of cardiac dysfunction (patients with 
clinical cardiac dysfunction or a low LVEF during the 12-month reporting period) were 
assessed using logistic regression and presented with odds ratios and 95% CIs. 
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Statistical analysis was on an intention-to-treat basis and therefore all patients were 
analyzed within their randomized treatment arms. All reported p-values are two-sided. 
Analysis was undertaken by Warwick Clinical Trials Unit, using SAS statistical 
software (version 9.3), following the pre-defined trial Statistical Analysis Plan. 
Persephone is registered with EudraCT (2006-007018-39), ISRCTN (52968807), and 
ClinicalTrials.gov (NCT00712140). 
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RESULTS 
Patients 
The first 2500 patients were randomized into the Persephone trial between October 
2007 and December 2012 (Figure 1); 1251 were randomized to 12-months and 1249 
to 6-months trastuzumab. These subgroups appeared balanced across treatment 
arms in terms of patient characteristics and prognostic variables (Table 1), and were 
representative of the whole Persephone patient sample (values for all 4088 patients 
shown in parenthesis): median age 55 years (56 years); 94% white (93%); 61% post-
menopausal (61%); 67% ER positive (69%); 48% <=2cm diameter (49%); 67% grade 
3 (66%); and 58% node negative (59%). During follow-up 59/2500 (2.4%) of the 
patients recurred (local or distant) within 12 months of starting trastuzumab. 
 
Chemotherapy, cardiac medication prior to trastuzumab and timing of 
randomization 
93% (2335/2500) of patients received an anthracycline as part of either anthracycline-
based (48% [1199/2500]) or anthracycline plus taxane-based (45% [1136/2500]) 
chemotherapy. 65% received trastuzumab sequentially to chemotherapy and 35% 
concomitantly with the non-anthracycline component. Full chemotherapy details are 
shown in Tables 1 and 2. Only 2% (50/2500) of patients, balanced across randomized 
treatment arms, reported being on cardiac medication prior to start of trastuzumab 
(Table 1). Randomisation was before the start of trastuzumab or at any time before 
the 10th cycle. 55% (1365/2500) were randomized up-front, and 82% (2039/2500) prior 
to cycle 4 (Supplementary Table 1), balanced across randomised treatment arms.  
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Trastuzumab modifications 
Complete trastuzumab treatment data are available on 2433 (97%) of the 2500 
patients (Figure 1). Of those randomized to the12-month arm, 85 (7%) received 1-9 
cycles and 1129 (93%) received >10 cycles of trastuzumab (Figure 1 and Supp Figure 
1). Of those randomised to the 6-month arm, 1165 (96%) received 1-9 cycles and 51 
(4%) received >10 cycles of trastuzumab. Three patients received no trastuzumab 
within the trial due to the diagnosis of metastatic disease. Cardiotoxicity was the most 
common reason for stopping treatment early (n=141) (Supp Figure 1), followed by 
patient request (n=76). Cardiotoxicity was also given as the reason for more 
trastuzumab delays in 12-month than 6-month patients (6% vs 4% of patients (p=0.01) 
(Table 3). Significantly more 6-month patients (1066/1164 [92%]) received at least 
85% course delivered dose intensity (CDDI), compared with 12-month patients 
(963/1142 [84%]) (p<0.0001). 
 
Cardiac events 
Full clinical cardiac data were available on 2430 patients (97%). Clinical cardiac 
dysfunction was more common in 12-month than 6-month patients (140/1214 [12%] 
vs 105/1216 [9%] respectively, p=0.02) (Table 4). No differences were apparent in the 
first 6 months of trastuzumab (8% of 12-month patients, 7% of 6-month patients 
[p=0.19]). However, a significant difference appeared during the 7-12 months period 
(8% vs 5% respectively [p=0.03]).  
 
A total of 12,147 LVEF measurements (71% ECHO, 17% MUGA, 12% unknown) were 
reported in 2498 patients. The use of each modality was balanced across randomized 
treatment arms. MUGAs appear to have a higher rate of abnormal scores (MUGAs 
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10% abnormal compared to 4% for ECHOs, Table 4). During the first 6 months of 
treatment, 7% of 12-month patients and 8% of 6-month patients recorded low LVEFs 
(p=0.76). During months 7-12, this increased to 8% of 12-month patients but fell to 5% 
of 6-month patients (p=0.004 for difference between treatment arms). Similarly, during 
the first 6 months of treatment, equal proportions of patients across randomized 
treatment arms recorded significant LVEF falls from baseline, with a similar proportion 
observed in the second 6 months for 12-month patients, but lower for 6-month patients 
(Table 4).  
 
Four cardiac deaths were reported. One was assessed as non-cardiac since at the 
time of death from liver metastases, the patient had well controlled NYHA II heart 
failure. In the other 3 patients post-mortem examination demonstrated ischaemic heart 
disease as the cause of death. In 2 of these 3 patients, all LVEF measurements during 
the 12 months of the trial were normal.   
 
Relative change of LVEF at 6 and 12 months  
2420 patients had an LVEF measured at baseline and at least one other time-point; 
1204 12-month and 1216 6-month patients (Supp Table 2). The two treatment arms 
were well matched for baseline LVEF (12-month median 63% [IQR 59-67%], 6-month 
median 63% [IQR 60-67%], p=0.22). There were statistically significant reductions in 
LVEF at the 6 and 12 month time-point in both treatment arms (all p<0.0001). Although 
similar relative changes from baseline to 6 months were seen across treatment arms 
(12-month median 0.97 [IQR 0.90-1.02], 6-month median 0.97 [IQR 0.90-1.02, 
p=0.38), 12-month patients showed significantly greater reductions in LVEF by 12 
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months (12-month median 0.96 [IQR 0.89-1.02], 6-month median 0.97 [IQR 0.91-1.03, 
p=0.001). 
 
Landmark cardiac dysfunction analysis from 6 months  
Cardiac data were available from 2081 patients who were free of cardiac events in 
their first 6 months of treatment. Significantly more 12-month patients (66/1046 [6%]) 
than 6-month patients (29/1035 [3%]) were recorded to have a cardiac event in the 
second 6 month period (p=0.0002). 
 
Random effects modelling 
A quadratic curve was found to fit the LVEF data, demonstrating that cardiac function 
recovers post treatment (Figure 2). This was seen for the entire trial population 
(p<0.0001) and for each randomized arm separately (both p<0.0001). There was a 
significant difference between treatments in terms of their change over time (p=0.02); 
quadratic modelling predicts an earlier recovery of cardiac function after treatment 
completion in 6-month patients. No significant differences were found between 
chemotherapy types (p=0.43) or trastuzumab timing (p=0.79) in terms of LVEF 
changes over time (Supp Figure 2A and 2B). 
 
Predictive factors for cardiac dysfunction 
For both 12-month and 6-month patients, lower baseline LVEF increased the odds of 
cardiac dysfunction (reference >65%: 55-<65% OR 1.61 [95%CI 1.26-2.04]<55% OR 
5.22 [95%CI 3.42-7.95])(Table 5). Additionally, increasing age was found to be linked 
to increasing odds of cardiac dysfunction (reference <50: 50-59 OR 1.58 [95%CI 1.17-
2.12], 60-69 OR 1.91 [95%CI 1.42-2.57]) 70+ OR 2.72 [95%CI 1.82-4.08]). 
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Chemotherapy type, left-sided radiotherapy, BMI and ethnicity did not appear to 
influence this endpoint. Receiving >3 cycles of anthracycline was associated with 
increasing odds of developing cardiac dysfunction in the 12-month trastuzumab arm 
(OR 1.41 [95%CI 1.04-1.90]), but not the 6-month arm (OR 1.28 [95%CI 0.91-1.79)]. 
Further random effects modelling showed that >3 compared with <3 cycles of 
anthracycline showed a non-significant trend to lower LVEF and slower recovery in 
the 12-month (p=0.19) but not the 6-month arm (p=0.70) (Supp Figure 3A and 3B). In 
the small number of patients who were taking cardiac medication prior to starting 
trastuzumab (25 in the 12-month arm and 23 in the 6-month arm) both arms were at 
significantly increased risk of developing cardiac dysfunction; 12-month patients had 
higher risk than 6-month patients (OR 12.47 [95%CI 5.14-30.25] v 5.88 [95%CI 2.55-
13.54] respectively). 
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DISCUSSION 
Trastuzumab is a highly effective adjuvant treatment for HER2 positive early breast 
cancer given in addition to chemotherapy. However, cardiotoxicity has been 
demonstrated consistently in patients receiving trastuzumab. In 2500 patients in the 
Persephone trial, we compared cardiotoxicity between the 6- and 12-month arms. 
Significantly more clinical cardiac dysfunction was seen in 12-month patients 
compared with 6-month patients (13% v 10%; p=0.04), and twice as many 12-month 
as 6-month patients stopped early because of cardiac events (8% v 4%: p<0.0001). 
Consequently, fewer 12-month than 6-month patients received course delivered dose 
intensity of >85% (84% vs 92%: p<0.0001). These data are similar to those reported 
from the PHARE trial (Pivot et al, 2015). In addition, the HERA trial (Procter et al, 2010) 
has reported an increased number of patients who developed clinical cardiac 
dysfunction and reduced LVEF measurements in the 24-month trastuzumab arm. 
Since 24 months treatment has not been shown to be more effective than the standard 
of 12 months and caused more cardiotoxicity, 12 months treatment remains the 
standard at present. 
 
Could the risk of cardiac dysfunction from trastuzumab be decreased by reducing the 
length of adjuvant treatment?  In the Persephone trial the principal research question 
concerns the non-inferiority for disease-free survival of 6 months compared with the 
standard of 12 months. In accordance with the trial statistical analysis plan, the primary 
endpoint will be analyzed in late 2017. If 6 months treatment proves to be non-inferior 
to 12 months in terms of disease-free survival, then the reduced cardiac problems 
reported for 6-months trastuzumab will provide an additional reason to adopt 6 months 
in place of the standard 12 months treatment.  
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Our modelling of the LVEF measurements on the whole population shows some 
interesting comparisons between the 6 and 12 month arms. Both appear to fit best into 
a quadratic model during treatment and on recovery. For the 12-month arm, the LVEF 
data show a lower LVEF nadir and a slower recovery than for the 6-month arm. This 
suggests that the longer the trastuzumab treatment, the greater the cardiac 
dysfunction and the longer the recovery time. This effect may not be limited to those 
with LVEF falls to <50% and could potentially result in long term susceptibility to 
adverse cardiac events because of a longer, more marked period of myocardial stress. 
These findings would be another reason to reduce adjuvant trastuzumab to 6 months 
if this length of treatment proves non-inferior to 12 months. 
 
The methods used to measure LVEF highlighted some interesting issues. ECHO was 
more frequently used (71% of cases) than MUGA (17% of cases), however MUGAs 
had 10% abnormal values compared with only 4% for ECHOs. It is possible that 
MUGAs are more sensitive than ECHOs, or alternatively that MUGAs were the 
‘preferred’ modality when cardiac problems were suspected on clinical grounds. 
Moreover in some hospitals the normal range of LVEF measured by MUGA is lower 
(e.g. >43%) than that for ECHO (≥55%), which means that it is more likely that a MUGA 
result will be <50%. In our analysis, following National Guidelines we took a cut-off of 
50% regardless of modality of assessment and this is likely to have influenced the 
incidence of ‘abnormal’ results, for the MUGA investigations. 
 
Some researchers have reported genetic alterations within the HER2 receptor that 
may predispose to cardiac toxicity from trastuzumab (Beauclair et al, 2007; Ng et al, 
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2014; Halyard et al, 2009). In a companion translational pharmaco-genetic research 
study (Persephone PGSNPs), a blood sample collection is in progress which will allow 
us not only to validate these potential predictive genetic alterations but also in a 
genome-wide association study, to discover other possible genetic predisposition 
factors for trastuzumab-induced cardiotoxicity.  
 
Our study shows that regardless of 6 or 12-month therapy, both age and baseline 
LVEF are important predictive factors for cardiac dysfunction. As a surrogate for 
radiotherapy effects we compared patients who had right with those with left sided 
tumors. Despite other reports of increased cardiotoxicity after radiotherapy for left-
sided HER2 positive breast cancer (Roca et al, 2013), we did not find an interaction 
with radiotherapy and sidedness, although the follow-up is relatively short. In terms of 
age, comparing patients under 50 years, with those in the next two decades, and those 
over 70 years, shows an increasing risk with age. Those over 70 years have an odds 
ratio of 2.63 for cardiac dysfunction, which would suggest that the predicted benefit of 
trastuzumab in this age group would have to be significant to balance the risk of 
cardiac dysfunction. In terms of lower baseline LVEF, patients with LVEF between 50 
and 55%, have an odds ratio of 5.36 [95% CI 3.53-8.14]) of developing cardiac 
dysfunction with low LVEF measurements when compared to a reference of >65%. 
However, these data should be interpreted cautiously since if a patient is at baseline 
close to the lower limit of normal LVEF value (50%), then even a small absolute % 
LVEF fall, possibly not clinically meaningful, would take them below this normal 
threshold. Anthracyclines have been demonstrated to significantly compound 
trastuzumab cardiotoxicity, nowhere more elegantly that in the BCIRG trial (Slamon et 
al, 2011) which excluded anthracyclines in one experimental arm. In many studies this 
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interactive effect is significantly greater when more than 3 cycles of anthracycline are 
given. Our study is the first to observe a differential effect between 6 and 12 months 
of trastuzumab therapy, with more than 3 cycles of anthracycline predicting a higher 
risk of cardiac toxicity in the 12-month but not the 6-month arm (OR 1.41 [95% CI 1.04-
1.90] and 1.28 [0.91-1.79] respectively). Although Slamon and colleagues have shown 
that anthracyclines can be substituted by carboplatin and long term outcomes are not 
significantly different, nevertheless anthracyclines are highly effective 
chemotherapeutic agents (Poole et al, 2006) and are still received by the majority of 
breast cancer patients in the adjuvant setting. In addition CEP17 and topo-isomerase 
II amplification (more common in the HER2 positive population) have been reported in 
a meta-analysis to be predictive biomarkers of anthracycline benefit (Bartlett et al, 
2015). Controversy remains with regards to discontinuing the use of anthracyclines 
altogether in HER2 positive disease, and therefore we should endeavor to develop 
guidance to maximise the cardiac safety of the anthracycline / trastuzumab 
combination. 
 
Often clinical trials exclude patients with common risk factors. This can limit the 
general applicability of their results and significant genetic differences have been 
demonstrated between patients in clinical trials and those included in the Cancer 
Genome Atlas (Geifman and Butte, 2016). It is important to emphasise that the 
Persephone trial was designed to ‘map on to standard NHS practice’ in the ‘real world’: 
The patients included in the trial have the same cardiac risk profile as those receiving 
standard chemotherapy followed by 12 months trastuzumab. This has important 
implications for the interpretation and applicability of the results of this cardiology sub-
study and of the future non-inferiority comparison of efficacy. 
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In conclusion, in the 2500 patient Persephone cardiology sub-study, patients on the 
6-month arm had significantly fewer cardiac events than the 12-month patients, 
particularly if they had received >3 cycles of anthracyclines. 
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